Compare BridgeBio Pharma Inc (BBIO) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Noble Corporation plc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Noble Corporation plc trades at $44.25 (market cap $6.51B). The key difference: BridgeBio Pharma Inc is far larger — about 2.6× Noble Corporation plc's market cap, and Noble Corporation plc pays a 4.91% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | NE | |
|---|---|---|
Market Cap | $16.61B | $6.51B |
Sector | Health | Technology |
52-Week High | $90.17 | $54.37 |
52-Week Low | $47.29 | $26.61 |
Enterprise Value | $18.16B | $7.94B |
Dividend Yield | — | 4.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Noble Corporation (NE) trades at $40.77, up 0.2% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 earnings of $0.01 per share, missing estimates, while revenue declined to $3.1B in 2026 from $3.3B in 2025. Recent news includes a fraud investigation announcement and new drilling contracts, creating investor uncertainty amid operational challenges.
The outlook remains cautious with analyst consensus at Buy (31%) and a $46 price target offering 13% upside. Key risks include earnings volatility, legal scrutiny, and competitive pressures in offshore drilling. Positive cash flow and dividend payments provide some stability, but execution on new contracts and margin improvement are critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
